Physician profile
Daniel J Flaherty
NPI 1659339976
$859.50
in general payments reported to CMS, 2019-2025
9 companies · $118 in 2025
The $118 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $58.05 · 2021: $248 · 2022: $165 · 2023: $161 · 2024: $110 · 2025: $118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $389.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $389.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $541.28 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $205.09 | 2021-2025 | |
| Amgen INC. | $24.57 | 2025 | Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.28 | 2021 | |
| Lilly USA, LLC | $19.37 | 2023 | Mounjaro |
| Sanofi-Aventis U.S. LLC | $18.99 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $15.03 | 2021 | |
| Astellas Pharma US INC | $12.89 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Flaherty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.